Motivation: Vaccines represent the most effective and cost-efficient weapons against a wide range of diseases. Nowadays new generation vaccines based on sub-unit antigens reduce adverse effects in high risk individuals. However, vaccine antigens are often poor immunogens when administered alone. Adjuvants represent a good strategy to overcome such hurdles, indeed they are able to: en- hance the immune response; allow antigens sparing; accelerate the specific immune response; and increase vaccine efficacy in vulnerable groups such as newborns, elderly or immuno-compromised people. However, due to safety concerns and adverse reactions, there are only a few adjuvants ap- proved for use in humans. Moreover, in practice current adjuvants sometimes fail to confer adequate stimulation. Hence, there is an imperative need to develop novel adjuvants that overcome the limita- tions of the currently available licensed adjuvants.Results: We developed a computational framework that provides a complete pipeline capable of predicting the best citrus-derived adjuvants for enhancing the immune system response using, as a target disease model, influenza A infection. In silico simulations suggested a good immune efficacy of specific citrus derived adjuvant (Beta Sitosterol) that was then confirmed in vivo.Availability: The model is available visiting the following URL: http://vaima.dmi.unict.it/AdjSim

A computational model to predict the immune system activation by citrus derived vaccine adjuvants

Pennisi Marzio;Russo Giulia;LEOTTA, MARCO;Pappalardo Francesco;PEDRETTI, ALESSANDRO;Motta Santo
2016-01-01

Abstract

Motivation: Vaccines represent the most effective and cost-efficient weapons against a wide range of diseases. Nowadays new generation vaccines based on sub-unit antigens reduce adverse effects in high risk individuals. However, vaccine antigens are often poor immunogens when administered alone. Adjuvants represent a good strategy to overcome such hurdles, indeed they are able to: en- hance the immune response; allow antigens sparing; accelerate the specific immune response; and increase vaccine efficacy in vulnerable groups such as newborns, elderly or immuno-compromised people. However, due to safety concerns and adverse reactions, there are only a few adjuvants ap- proved for use in humans. Moreover, in practice current adjuvants sometimes fail to confer adequate stimulation. Hence, there is an imperative need to develop novel adjuvants that overcome the limita- tions of the currently available licensed adjuvants.Results: We developed a computational framework that provides a complete pipeline capable of predicting the best citrus-derived adjuvants for enhancing the immune system response using, as a target disease model, influenza A infection. In silico simulations suggested a good immune efficacy of specific citrus derived adjuvant (Beta Sitosterol) that was then confirmed in vivo.Availability: The model is available visiting the following URL: http://vaima.dmi.unict.it/AdjSim
Computational modeling; Multi-scale modeling; Bioinformatics
File in questo prodotto:
File Dimensione Formato  
2016_Pappalardo et al._Bioinformatics.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Dimensione 354.28 kB
Formato Adobe PDF
354.28 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11769/48576
Citazioni
  • ???jsp.display-item.citation.pmc??? 17
  • Scopus 36
  • ???jsp.display-item.citation.isi??? 32
social impact